2.38
-0.015(-0.63%)
Currency In USD
| Previous Close | 2.39 |
| Open | 2.38 |
| Day High | 2.42 |
| Day Low | 2.38 |
| 52-Week High | 8.8 |
| 52-Week Low | 2.11 |
| Volume | 22,395 |
| Average Volume | 63,083 |
| Market Cap | 7.17M |
| PE | -0.95 |
| EPS | -2.51 |
| Moving Average 50 Days | 2.48 |
| Moving Average 200 Days | 3.01 |
| Change | -0.02 |
If you invested $1000 in Biomerica, Inc. (BMRA) since IPO date, it would be worth $245.35 as of January 31, 2026 at a share price of $2.375. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 4 years ago, it would be worth $43.98 as of January 31, 2026 at a share price of $2.375.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
GlobeNewswire Inc.
Jan 14, 2026 10:17 PM GMT
Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagno
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
GlobeNewswire Inc.
Dec 23, 2025 1:19 PM GMT
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after Ja
Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
GlobeNewswire Inc.
Dec 11, 2025 1:08 PM GMT
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection